Consumer Health Products Regulatory Roundup
This article was originally published in The Tan Sheet
Weight loss product firms touch all the bases in advertising violations; a scoop too small in children's nutritional; and another sibutramine-spiked supplement found.
You may also be interested in...
$500,000 fine in $1.3m FTC judgement; and Hormel and NuSkin nutritional products recalled.
Public Company Edition: Cancer-focused Adlai Nortye launched a concurrent initial public offering and private placement, while four other drug developers announced or completed SPAC mergers. Also, Sobi grossed $540m in a rights issue and Immunovant followed early data with a $450m FOPO.
The company anticipates potential sales in excess of $1bn for the late-onset Pompe disease drug by the end of the decade.